Ipamorelin vs Sermorelin: GHRP vs GHRH Comparison for GH Secretion | Peptpedia

Ipamorelin is a selective GHRP that acts on the GHSR-1a ghrelin receptor on pituitary somatotrophs and hypothalamic neurons. It amplifies GH pulse amplitude and partially suppresses somatostatin (the physiological GH brake). Its selectivity makes it unique among GHRPs: it does not stimulate cortisol, ACTH, or prolactin release at research doses, unlike GHRP-6 and GHRP-2.

Sermorelin is the first 29 amino acids of native GHRH-44, the minimum sequence required for full GHRH receptor activation. It stimulates GH release through the pituitary GHRH receptor, increasing GH pulse frequency through a cAMP-mediated pathway. Because it relies on functional hypothalamic-pituitary axis integrity, Sermorelin's effects are more physiological and subject to the normal somatostatin feedback loop.

Ipamorelin has a plasma half-life of approximately 2 hours, with peak GH secretion occurring 30-40 minutes after subcutaneous administration. Pharmacokinetic-pharmacodynamic modeling has characterized a clear dose-response relationship with a sigmoidal Emax model describing GH release kinetics (PMID 10496658). The relatively long half-life for a GHRP allows sustained receptor engagement through a single daily injection in most research protocols.

Sermorelin has a substantially shorter half-life of approximately 10-20 minutes, producing a rapid but brief GH pulse followed by quick clearance. This pharmacokinetic profile more closely mimics the endogenous pulsatile pattern of GHRH release but requires more frequent dosing to maintain therapeutic GH elevation. Peak GH response occurs within 15-30 minutes of subcutaneous injection.

The combination of a GHRP (such as Ipamorelin) with a GHRH analog (such as Sermorelin) produces synergistic, supra-additive GH release — typically 2-3 fold greater than either agent alone. This GHRP + GHRH combination has become the standard research protocol for maximizing pituitary GH output while maintaining physiological feedback mechanisms.

Sermorelin has the more substantial clinical and regulatory history. It received FDA approval as Geref Diagnostic (for GH deficiency diagnosis) and later as Geref (for pediatric idiopathic GH deficiency treatment). The drug was commercially withdrawn from the US market in 2008 — notably for commercial reasons (manufacturing and market economics), not due to safety concerns. This regulatory history provides a human safety dataset that Ipamorelin lacks.

Ipamorelin entered a Phase 2 clinical trial for postoperative ileus (NCT00272649), an application leveraging the prokinetic effects of ghrelin receptor agonism on gastrointestinal motility. The trial was discontinued. Beyond this, Ipamorelin's human data derives primarily from early-phase pharmacology studies rather than efficacy trials. Raun et al. (1998) established Ipamorelin as the first selective GH secretagogue in the GHRP class (PMID 9849822), demonstrating its unique selectivity profile in preclinical models.

Sermorelin retains the larger body of formal human clinical data, including pediatric efficacy data and long-term safety observations from its period of clinical use.

Ipamorelin remains the preferred GHRP in contemporary research protocols due to its selectivity profile. Unlike GHRP-6 and GHRP-2, Ipamorelin does not stimulate cortisol, prolactin, or appetite at research doses — a clean pharmacological profile that reduces confounding variables in GH-focused studies. Bowers (1984) first characterized the GH-releasing activity of synthetic hexapeptides that laid the groundwork for Ipamorelin's development (PMID 6714155).

CJC-1295 (with or without Drug Affinity Complex) has largely replaced Sermorelin as the GHRH component in modern research protocols. The rationale is pharmacokinetic: CJC-1295 with DAC has an effective half-life of 6-8 days compared to Sermorelin's 10-20 minutes, enabling weekly rather than daily dosing. Modified GRF(1-29) (CJC-1295 without DAC, also called MOD-GRF) offers an intermediate half-life of approximately 30 minutes.

The standard modern research protocol pairs Ipamorelin with CJC-1295 (no DAC) for a GHRP + GHRH combination that achieves supra-additive GH release with clean selectivity and practical dosing frequency. Sermorelin, while historically important and clinically validated, is now used primarily when a shorter-acting, more physiological GHRH stimulus is specifically desired.